In the adult nervous system, neurotransmitters play a central role in driving communication between neurons. In the developing nervous system, neurotransmitters such as serotonin and acetylcholine (ACh) contribute to various phases of development including neurogenesis, cell differentiation, and the formation of synapses (Erskine and McCaig 1995; Rudiger and Bolz 2008) . The cerebral cortex and hippocampus receive ACh innervation from the basal forebrain, medial septum, and vertical diagonal band (Bruel-Jungerman et al. 2011) . Beginning prenatally and continuing through early adulthood, the cholinergic signal informs neural connectivity by modulating the growth and retraction of axons (Elsas et al. 1995; Luo and O'Leary 2005) and the formation of local dendritic fields within hippocampal neurons (Campbell et al. 2010; Lozada et al. 2012) .
Cholinergic signaling is dependent on the activation of the G protein-coupled muscarinic receptor and nAChRs (Jones et al. 2012) . In the adult hippocampus, a7 is expressed preand post-synaptically, contributing to GABA and glutamate neurotransmission (Liu et al. 2006; Lozada et al. 2012) . Although studies show that a7 regulates neural development in the cortex and hippocampus (Coronas et al. 2000; Liu et al. 2006; Lozada et al. 2012) , its mechanism of action is ill defined.
Several nAChRs have been found to interact with G proteins and contribute to intracellular signaling in neurons (Fischer et al. 2005; Kabbani 2007; Paulo et al. 2009; Nordman and Kabbani 2012) . Recently, we have shown that coupling to a G protein complex consisting of G proteinregulated inducer of neurite outgrowth 1 (Gprin1), the heterotrimeric GTP-binding subunit Gao, and growth-associated protein 43 (GAP-43) enables a7 to regulate neurite growth (Nordman and Kabbani 2012) . To determine the role of a7 in brain development, we have examined the effect of a7/Gprin1 interaction in cultured hippocampal neurons. We find that a7 activation contributes to calcium signaling and inhibition of axon growth via a Gprin1 pathway.
Materials and methods
Neuronal cultures, transfection, and drug treatment Primary hippocampal neurons were obtained from post-natal day 1 (P1) male and female Sprague-Dawley rats (Charles River, Frederick, MD, USA) as described (Nunez 2008) in accordance with the Institutional Animal Care and Use Committee (IACUC) and ARRIVE guidelines. Neuronal cultures were grown in Neurobasal media with B27 supplement and 1% Pen-strep. Serum was withdrawn 12 h after plating to minimize glial growth. A knockdown in a7 expression (a7-) was obtained by transducing high-titer lentiviral stocks of short hairpin RNAs representing a7 RNAi (Lozada et al. 2012) into hippocampal neurons. A scrambled a7 RNAi was used as a transduction control (Lozada et al. 2012) . Knockdown in Gprin1 expression (Gprin1-) was obtained by transfecting Gprin1 siRNA in pRNAT H1.1 into hippocampal neurons. Gprin1 vectors have been described previously (Ge et al. 2009; Nordman and Kabbani 2012) . Neurons were transfected using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA). Unless otherwise stated, an empty plasmid corresponding to the transfected protein vector was used as a control in the assay.
Drug concentrations were determined based on published studies (Chan and Quik 1993; Strittmatter et al. 1994; Swarzenski et al. 1996; Khiroug et al. 2002; El Kouhen et al. 2009 ): a-Bungarotoxin (Bgtx) (50 nM, Sigma, St Louis, MO, USA); PNU282987 (PNU) (1-10 lM, Sigma); pertussis toxin (Ptx) (1 lM, Calbiochem, San Diego, CA, USA); mastoparan (30 lM, Tocris, Bristol, UK); and choline (1 mM, Acros, Geel, Belgium). Drug treatment experiments were performed in triplicate and the data presented represent the average for each condition. Prior to initiation of the assay, the effect of drug concentration on cell viability and health was pre-established using trypan blue (EMD).
Immunochemical detection of proteins in brain slices and cultured cells Hippocampal brain slice preparation and immunohistochemistry were preformed as described in Lozada et al. (2012) . Briefly, P5 and P30 rats were anesthetized using 5% isofluorane and then perfused using 4% paraformaldehyde, pH 7.2. Brains were dissected and submerged in 4% paraformaldehyde for 24 h before being transferred to 30% sucrose for cryoprotection. The tissue was then embedded in 5% agarose and sectioned into 30-lm slices using a vibrating blade microtome (Thermo Scientific, Waltham, MA, USA). For immunohistochemistry, brain slices were permeabilized using 0.5% Triton X-100 and quenched by 50-mM ammonium chloride for 30 min at 25°C. Tissue was blocked in 10% goat serum prior to being probed with the a7 ligand fluorescein-conjugated Bgtx (fBgtx) (Molecular Probes, Eugene, OR, USA), a polyclonal rabbit anti-Gprin1 antibody (Ab) (Abcam, Cambridge, MA, USA), and a polyclonal mouse anti-Tau-1 Ab (Millipore, Billerica, MA, USA) overnight at 4°C. Tissue was reblocked in 10% goat serum followed by immunoprobing with a Dylight 560 secondary anti-rabbit Ab and an Alexafluor 647 secondary anti-mouse Ab for Gprin1 and Tau-1 detection, respectively (Jackson-ImmunoResearch, West Grove, PA, USA).
Background autofluorescence was accounted for using the secondary Ab alone.
Cellular immunostaining was carried out as described in He et al. (2005) . Briefly, cultured neurons were fixed in 19 PEM (80 mM PIPES, 5 mM EGTA, and 1 mM MgCl2, pH 6.8) containing 0.3% glutaraldehyde, and then permeabilized at 25°C in 0.05% Triton X-100 prior to glutaraldehyde quenching with 10 mg/mL sodium borohydride. Cells were blocked in 10 mg/mL bovine serum albumin + 10% goat serum prior to being immunostained overnight at 4°C with the following primary Abs: mouse anti-Tau-1; anti-Gprin1; pGAP-43; GTP-CDC42 (New East, King of Prussia, PA, USA). Secondary Abs used (all purchased from Jackson-ImmunoResearch): carbocyanine (Cy) 2/3; Dylight 488; Dylight 560; and AlexaFluor 647. a7 was visualized using fBgtx. F-actin was visualized using Rhodamine Phalloidin (Cytoskeleton). All staining was visualized using a Nikon Eclipse 80i confocal microscope (Melville, NY, USA) fitted with a Nikon C1 CCD camera and images were captured using AxioVision and EZ-C1 software (Thornwood, NY, USA).
For protein distribution analysis in immunostainings, brain slices and cells in culture were analyzed for co-localization and distribution of a7 and Gprin1 by first thresholding the individual signals to reduce background (Lozada et al. 2012 ) and then merging the two signals using ImageJ (NIH, Bethesda, MD, USA). For brain slices, the colocalized a7/Gprin1 signal was measured in various compartments according to overlap with DIC. Distribution analysis was conducted by measuring the signal within a 1 lm 2 area for neurons or a 25 lm 2 area for brain slices sufficient for analysis at the single neuron level. Analysis was conducted in Tau-1 positive (Tau-1+) cultured hippocampal neurons. All data are based on averages from three separate independent experiments.
Protein isolation and detection
Solubilized membrane protein fractions (membrane proteins) of hippocampal cells were obtained using a published protocol optimized for nAChRs . Immunoprecipitation (IP) of receptor-protein complexes for a7 was optimized and described previously (Nordman and Kabbani 2012) . In brief, proteins were solubilized overnight at 4°C using a solution of 1% Triton X-100, 137 mM NaCl, 2 mM EDTA, and 20 mM Tris-HCl (pH 8) with a 19 protease inhibitor cocktail (Complete, Roche, Indianapolis, IN, USA) and a 19 phosphatase inhibitor cocktail (Sigma). Protein concentrations were obtained using the Coomassie Protein Assay reagent (Thermo Scientific). IP experiments were performed by first incubating membrane proteins with an anti-a7 monoclonal Ab (mAb306; Lindstrom et al. 1990) or an anti-Gprin1 rabbit polyclonal Ab (Abcam) followed by extraction using protein G Dynabeads (Invitrogen). Control IP experiments were performed by incubating the same amount of membrane proteins (MP, 100 lg) with an equal amount of a pure polyclonal rabbit IgG Ab (5 lg) (Cell Signaling Technology, Beverly, MA, USA).
Western blot detection was obtained using nitrocellulose membranes blocked with 5% non-fat milk (or 1% bovine serum albumin for biotinylation experiments). Membranes were probed with the following primary Abs overnight at 4°C: a7 nAChR (SC); Gprin1; HCN1 (SC); GAP-43 (Abcam); pGAP-43; CDC42 (SC); GTP-CDC42; glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (Cell Signaling). Species-specific peroxidase-conjugated secondary Abs were purchased from Jackson-Immunoresearch. Signals were detected using the SuperSignal West Pico Chemiluminescent Substrate (Thermo Scientific) with SeeBlue and MagicMark (Invitrogen) as molecular weight standards. Blots were imaged using the Gel Doc Imaging system (Bio-Rad Laboratories, Hercules, CA, USA). Band density analysis was performed using ImageJ version 10.2 (NIH). Western blot values are based on averages from three separate independent experiments.
Growth cone purification
The growth cone (GC) fraction was prepared as described in Lohse et al. (1996) . In brief, hippocampi pooled from a litter of P0 rat pups were homogenized in 1-mM TES buffer (50 mM Tris-HCl, pH 8.0, 5 mM EDTA, 51 mM NaCl) supplemented with 1-mM MgCl2, 0.32-M sucrose, and protease (Complete) and phosphatase (Sigma) inhibitors. The homogenate was spun at low-speed centrifugation (1660 g) and the supernatant was collected then layered over a sucrose gradient of 0.83 M and 1.0 M. Layered sample was then centrifuged at 242 000 g for 40-60 min at 4°C. The GC fraction was found at the 0.83-M interface, whereas the cell fraction was found at the 0.83-1.0 M fraction. GC proteins were solubilized for membrane protein enrichment using the method described earlier in this study.
Biotinylation of cell surface receptors
The quantification of proteins at the cell surface was conducted using a biotinylation protocol (Kabbani et al. 2002; Hannan et al. 2008) . In these experiments, 300 lg/mL EZ-Link Sulfo-NHS-LC-Biotin (Pierce, Rockford, IL, USA) was used to label cell surface proteins in living cells for 30 min at 4°C. The biotin reaction was quenched using tris-buffered saline, and membrane proteins were prepared as described previously . A neutravidin agarose bead matrix (Pierce) was used to pull down biotinylated proteins over a 30-lm pore size Snap Cap spin column (Pierce). Proteins were detected using western blot as described earlier. Biotin labeling was detected using horseradish peroxidaseconjugated streptavidin (Cell Signaling). Experiments were performed in triplicate and the data presented are the group averages.
Morphological and statistical analysis
Morphological reconstruction was performed using Neuromantic software (Myatt et al. 2012) . Tau-1+ axons were measured for surface area (SA) and branch number to assess size and complexity under various conditions. Only the primary axon was analyzed in each neuron. Neurons were readily visualized by Tau-1+ staining, and GCs were visualized by reactivity to rhodamine phalloidin. Group averages were derived from three separate experiments with 20-30 cells in each set. Statistical analysis was conducted on raw data of image tracing using Neuromantic. Statistical values have been obtained using a Student's t-test or one-way ANOVA. Asterisks indicate statistical significance in a paired Student's t-test, two-tailed p value, *< 0.05; **< 0.01; ***< 0.001. Error bars indicate standard error of the mean (SEM).
EB3 comet imaging
End-binding protein 3 (EB3) is a microtubule capping protein that binds to the plus end of polymerized microtubules during periods of assembly (Stepanova et al. 2003) . Hippocampal neuronal cultures were transfected with red fluorescent protein (RFP) conjugated EB3 and the indicated cDNA plasmids using Lipofectamine 2000 at 60 h after plating (Liu et al. 2010) . EB3 comet imaging was performed 24 h later. Images were captured 1 frame per sec for 2 min at 2 9 2 binning using AxioVision. The images were quantified for the velocity of the comets that enter the growth cone filopodia (Nadar et al. 2008) . Cells were treated with PNU (1-10 lM), a combination of PNU 10 lM and 50 nM Bgtx, 0.1% dimethylsulfoxide (DMSO) as vehicle control, or an empty vector as a transfection control. The comet trajectories were traced in these experiments using ImageJ software (NIH). Experiments were performed in triplicate and the data presented are the group averages.
Calcium imaging
Calcium imaging was carried out as described previously (Del Negro et al. 2011 ) with minor modifications. P0 hippocampal neurons were cultured for 3 DIV before loading with the calcium dye Fluo-8 AM (SC). Cultures were washed with Hank's Balanced Salt Solution (HBSS) and then incubated for 20 min at 25°C in a dye-loading solution containing HBSS with 10-mM HEPES, 2.5-lM Fluo-8 AM, and 0.2% Pluronic acid F-127. Following incubation, the cultures were again washed in fresh HBSS and then immediately placed into a recording chamber perfused with artificial cerebrospinal fluid at a rate of 1 mL/min. We imaged Fluo-8 AMlabeled neurons using a fixed-stage Zeiss Axio Examiner A.1 with a 639/1.0 NA objective and a Rolera EMC 2 camera (Q-Imaging, Surrey, BC, Canada) imaged at 10 Hz. Phototoxicity was minimized through the use of low-wavelength polarized light filters. Image stacks were acquired at 70 Hz using a CCD camera (Andor Technology, South Windsor, CT, USA). The following drugs and their concentrations were diluted in artificial cerebrospinal fluid and administered via a perfusion system at 1 mL/min: PNU (10 lM); PNU and Bgtx (50 nM); choline (1 mM); choline and Bgtx. 0.1% DMSO was used as a vehicle control. An empty RFP vector was used as a transfection control. Regions of interest were analyzed using ImageJ (NIH) and normalized as DF/F 0 . Regions of interest were averaged over conditions. The data presented have been normalized to controls.
Mass spectrometry
Protein analysis was conducted using liquid chromatography electro spray ionization (LC-ESI) mass spectrometry (MS). Protein complexes were prepared as described (Kaiser et al. 2008 ) and mass spectrometry was carried out using a published protocol (de Luca et al. 2009 ). Tandem mass spectra collected by Xcalibur (version2.0.2, Thermo Scientific) were searched against the NCBI rat protein database using SEQUEST (Bioworks software from Thermo Scientific, version 3.3.1). The SEQUEST search results were filtered using the following criteria: minimum X correlation (XC) of 1.9, 2.2, and 3.5 for 1+, 2+, and 3+ ions, respectively, and DCn > 0.1. The protein score represents the XC where scores < 0.1 were excluded from the analysis and does not reflect the quantity of a protein in the sample.
Results
a7 and Gprin1 interact in the developing hippocampus a7 is expressed in the adult hippocampus where it can modulate the activity of excitatory and inhibitory neurons (Albuquerque et al. 1996 (Albuquerque et al. , 1998 . In hippocampal development, however, less is known about the expression and role of a7. We examined the distribution of a7 in the hippocampus at various stages of growth. Brains from post-natal day (P) 5 and 30 rats were probed for a7 expression using fluorescent-conjugated a-bungarotoxin (fBgtx). In addition, we co-immunolabeled the brain slices with an anti-Gprin1 Ab, which selectively recognizes Gprin1 (Nordman and Kabbani 2012) . As shown in Fig. 1a , co-expression of fBgtx and Gprin1 was detected in the developing hippocampus. This expression, although widespread, was not ubiquitous. In particular, the Gprin1 signal was found in cells that were immunoreactive for the axon-specific marker Tau-1, whereas fBgtx labeling was detected in Tau-1+ cells ( Fig. 1b) as well as those that exhibited immunoreactivity to the astrocytic marker glial fibrillary acidic protein (data not shown). These findings imply that whereas a7 expression in not limited to neurons, Gprin1 expression is predominantly neuronal.
We compared the expression of the two proteins during development. A fluorescence double signal (co-signal) for fBgtx and anti-Gprin1 within the cell was measured as previously described (Nordman and Kabbani 2012) . In preliminary experiments, the fBgtx signal was diminished by the addition of PNU (1 and 10 lM), confirming the specificity of the ligands on a7 ( Figure S1 ). As shown in Fig. 1a , the co-signal was more abundant during the early P5 stage of development. A quantitative assessment of the fluorescence co-signal was used to determine a7/Gprin1 coexpression in the hippocampus. As shown in Fig. 1a , a noticeable a7/Gprin1 co-signal was detected in CA3 and CA1 regions at P5. Immunolabeling with an anti-Tau-1 Ab confirmed that over 95% of the cells that displayed an a7/ Gprin1 co-signal are neurons ( Fig. 1b) . Hippocampal neurons are known to undergo apoptosis, maturation, and synaptic pruning during early post-natal development (Jordan et al. 1997; Riccomagno et al. 2012) . a7/Gprin1 co-expression was also detected in other regions of the hippocampus as well as the cortex and striatum (Fig. 1a ). Single-labeling experiments using fBgtx, anti-Tau-1, or anti-Gprin1 antibodies produced a signal consistent with the double-and triple-labeling results (data not shown).
Immunofluorescent findings indicate that a7/Gprin1 expression is highest after birth. To explore this, we examined the levels of the two proteins in hippocampal tissue by western blot. As indicted in Fig. 1c , the expression of a7, within membrane fractions of the developing hippocampus, appeared to peak at 1 and 4 days after birth. Similarly, the expression of Gprin1 displayed a consistent expression profile, i.e., peaking after birth then sharply declining to barely detectable levels in adulthood (Fig. 1c) . These results suggest a role for the two proteins in hippocampal development.
Immunoprecipitation was used to validate interactions between a7 and Gprin1 during hippocampal development. MP derived from P5 rat pups were used to immunoprecipitate Gprin1 and a7 proteins. The a7-specific Ab mAb306 and an anti-Gprin1 Ab were then used to immunoprobe for Gprin1 and a7 in the IP, respectively. As shown in Fig. 1d , immunoreactive bands for a7 and Gprin1 proteins were detected in the IP experiments. The identity of the proteins within the IP assay was also confirmed in parallel experiments utilizing MS analysis (Table S1 ) and previously (Nordman and Kabbani 2012 ). An hyperpolarization-activated cyclic nucleotide-gated channel type 1 (HCN1)-specific Ab was used as a negative control in the IP experiment. As shown, neither of the two IP Abs was found to co-IP HCN1 in the assay (Fig. 1d) , thus, supporting the specificity of the interaction between a7 and Gprin1 at the plasma membrane.
Localization of a7 and Gprin1 in axons and growth cones We examined expression of endogenous a7 and Gprin1 proteins in developing hippocampal neurons. At 3 days in vitro (DIV) hippocampal neurons extend axons capable of detecting and reacting to various external growth signals (Kater and Mills 1991) . As shown in Fig. 2, a7 and Gprin1 proteins were detected within developing hippocampal neurons using fBgtx and anti-Gprin1 Abs, respectively. The specificity of the Gprin1 Ab was verified in preliminary studies that showed a proportional decrease in the Gprin1 Ab signal following transfection with Gprin1 siRNA (data not shown). In particular, strong levels of a7 and Gprin1 coexpression were observed in the soma, at neurite branch points, and in the GC (Fig. 2a) . Growth cones and branch points are known to be active regions of growth and retraction (Lowery and Van Vactor 2009) . We find that a7/Gprin1 co-localization is highest at these regions of active growth suggestive of a role for the interaction in cytoskeletal remodeling and axon development.
The axon growth cone consists of three main zones: peripheral, transitional, and central. The central zone (CZ) is located at the base of the GC, nearest to the axon, and is composed of microtubules as well as various receptors and organelles (Lowery and Van Vactor 2009) . We find strong co-localization of a7 and Gprin1 within the CZ and, in some cases, the two proteins were detected in the filopodia of the GC (Fig. 2b) . A GC purification strategy (described in Materials and Methods) (Lohse et al. 1996) Ab was used to immunoprecipitate (IP) a7 and Gprin1 proteins from the GCF. Western blot detection confirms interaction of the two proteins. Protein identity was also determined by in-gel digest mass spectrometry (Table S2 ). IgG was used as an Ab control.
GC of the developing hippocampus. As shown in Fig. 2c , an anti-GAP-43 Ab was used to confirm the isolation of the GC compartment from hippocampal tissue. A western blot analysis reveals that a7 as well as Gprin1 are present within the GC consistent with our immunocytochemical finding. The interaction between the two proteins within the IP was also confirmed in parallel using MS analysis (Table S2 ). The above experiments demonstrate an a7/Gprin1 interaction within the GC of developing hippocampal neurons.
a7 regulates the structure of the growth cone and axon a7 has been shown to regulate neurogenesis and dendritic as well as axonal synaptic formation in the nervous system (Bromberg et al. 2008b; Lozada et al. 2012) . To examine the role of this receptor in early axon growth of hippocampal neurons, we examined the effect of the a7-specific agonist PNU282987 (PNU) on axon size and structure in hippocampal neurons. PNU is a known agonist at the a7 receptor site found to bind other nAChR ligands including Bgtx (El Kouhen et al. 2009 ). The stability of PNU and its resistance to neurotransmitter reuptake mechanisms make it an ideal experimental tool when attempting to selectively target a7. Newly formed axons were visualized using an antibody for the axon-specific microtubule protein Tau-1. We assessed the effects of PNU (1-10 lM) or a combination of PNU (10 lM) and the a7-specific antagonist a-Bungarotoxin (Bgtx) (50 nM) on axon growth. PNU treatment was associated with a significant, dose-dependent (10 lM) reduction in axon growth [À42% (AE 6%)], measured as total SA and branching number [47% (AE 7%)] (Fig. 3a) . In the presence of Bgtx, however, PNU did not significantly alter the growth and complexity of the primary axon relative to control-treated cells (Fig. 3a) . Group significance was observed between controls and PNU doses (1-10 lM) (SA: F(2,30) = 4.85, p < 0.01; branch: F(2,30) = 6.12, p < 0.01). These results reveal that pharmacological activation of a7 reduces axon growth and branching in hippocampal neurons. GC dynamics are instrumental in guiding the developing axon toward its final destination and have been shown to be a useful measure of real-time growth (Zheng and Poo 2007) . In particular, the innervation of microtubules into filopodia correlate with the directionality of axonal growth (Lowery and Van Vactor 2009) . We find high levels of a7 expression in the GC formation at the end of the primary axon branch ( Fig. 2a ). We hypothesize a role for a7 in regulating axon growth via the GC. To test this, we analyzed the structure of the GC in hippocampal neurons treated with the a7 agonist PNU (1-10 lM). We find a dose-dependent reduction in the number of GCs for each neuron [À44% (AE 10%)] and a reduction in filopodia number and size in each GC [À53% (AE 11%)] following PNU treatment and compared with vehicletreated controls (Fig. 3b) . Group significance was observed between controls and PNU doses (1-10 lM) (GC#/cell: F(2,30) = 5.13, p < 0.01; Filopodia#/GC: F(2,30) = 6.95, p < 0.01). In PNU (10 lM)-treated cells, GC and axon morphology were highly correlated (Table S3 ), suggesting that a7 activation inhibits growth uniformly throughout the cell. Similar to axon growth, Bgtx was found to abolish the effects of PNU (10 lM) on GC structure and number in a highly correlative manner (Fig. 3b , Table S3 ), underscoring the specificity of the a7 signal in these developmental effects.
To confirm the role of a7 in axon growth, hippocampal neurons were transduced with a7 RNAi or a scramble vector then analyzed for morphological changes in axon growth in the absence of drug treatment. As shown in Fig. 3c , cells expressing a7 RNAi (a7-) displayed significantly enhanced growth of axons [SA: +39.5% (AE 9%); branch number: +85.6% (AE 10%)] and growth cones [GC number/cell: +72.2% (AE 16%); filopodia number/cell: 53.4% (AE 11%)] compared with both the scramble controls and non-transfected cells (Fig. 3a-c) . The scramble vector was found to have no effect on axon growth. Similar findings were observed in hippocampal neurons treated with 50-nM Bgtx showing that inhibition of a7 promotes axon growth (data not shown). In light of earlier findings on PNU-mediated inhibition of axon growth, the current data supports the hypothesis that inactivation of a7 can augment neurite growth (Nordman and Kabbani 2012) .
We observed the effects of PNU treatment on cytoskeletal growth using the microtubule + end capping protein RFP-EB3 (EB3 comets), which has been utilized in analyzing real-time axon growth (Stepanova et al. 2003; Liu et al. 2010) . As shown in Fig. 3d , at 1 lM of PNU treatment, EB3 comets velocity was noticeably diminished relative to controls. At 10 lM of PNU, however, the velocity of the EB3 comets was not only significantly attenuated but also moved in a retrograde direction suggestive of growth cone collapse. Group significance was observed between controls and PNU doses (1-10 lM) (F(2,30) = 5.80, p < 0.01). The addition of Bgtx was found to significantly attenuate the effects of PNU treatment (10 lM) on EB3 comet velocity, and restored the directionality of comet movement to anterograde (Fig. 3d) .
Gprin1 is critical for a7-mediated growth Gprin1 can regulate neurite growth via its ability to bind and regulate large G proteins such as Gao, as well as small G proteins such as CDC42 (Chen et al. 1999; Nakata and Kozasa 2005) . We determined a role for Gprin1 in a7-mediated axon growth in hippocampal neurons by transfecting neurons with plasmids encoding short interfering RNA (siRNA) (Gprin1-), which has been shown to reduce Gprin1 expression in neural cells (Ge et al. 2009 ). Consistent with earlier findings, reduction in Gprin1 expression was associated with an overall decrease in neurite growth (Ge et al. 2009 ). When examining the effects of PNU on axon growth, we found that PNU has no effect on axon morphology in Gprin1-cells ( Fig. 4a ), suggesting that Gprin1 expression is necessary for a7 function. We confirmed the involvement of Gao in the a7/Gprin1 pathway. As shown in Fig. 4b , treatment of cells with the Gao activator mastoparan (MSP) was found to significantly enhance axon growth [axon SA: 31% (AE 11%); branch #: 47% (AE 4%); GC #/cell: 58% (AE 5%); filopodia #/cell: 45% (AE 4%)]. The effect of MSP was found sufficient to override PNU-mediated inhibition of axon growth suggesting that Gao operates downstream of a7. We confirmed this by also examining the role of the Gai/ o inhibitor PTX on axon development. Ptx exposure was associated with a significant reduction in axon growth [axon SA: À34% (AE10%); branch #: À41% (AE7%); GC #/cell: À40% (AE6%); filopodia #/cell: À47% (AE8%)] and this effect was not enhanced by PNU. Group significance was observed between controls, MSP, MSP+PNU, Ptx, and Ptx+PNU treated cells [SA: F(4,50) = 5.37, p < 0.01; Branch#: F(4,50) = 12.36, p < 0.001; GC#/Cell: F(4,50) = 12.79, p < 0.001; Filopodia#/Cell: F(4,50) = 14.01, p < 0.001], suggesting that a7 operates in a Gai/o pathway.
a7 signaling at the GC regulates GAP-43 and CDC42 A number of signaling pathways have been shown to regulate axon growth or direct its retraction by directing the assembly of the cytoskeleton (Lowery and Van Vactor 2009) . Studies demonstrate that activation of GAP-43 via its phosphorylation at Ser41 is critical for axon growth and branching (Kozma et al. 1997; Dent and Meiri 1998; Leu et al. 2010) . Similarly, the GTP activation of CDC42 (GTP-CDC42) functions as an important indicator of GC function (Kozma et al. 1997) . Recently, we demonstrated that a7 activation regulates GAP-43 phosphorylation in neurites (Nordman and Kabbani 2012) , while other studies have shown a role for Gprin1/Gao in the activation of CDC42 in the growth cone (Nakata and Kozasa 2005) . To test the role of a7 signaling in GAP-43 and CDC42 activation, we examined the effect of PNU (60-min treatment) on the phosphorylation of GAP-43 and the levels of GTP-CDC42 in hippocampal neurons. We find a significant reduction in phospho-GAP-43 (pGAP-43) (Zakharov and Mosevitsky 2007) 2012) levels in PNU-treated cells (Fig. 4c ). Decrease in pGAP-43 and GTP-CDC42 expression was especially pronounced in the GC (Fig. 4d) . The effect of PNU on GAP-43 phosphorylation and CDC42 activation was abolished in the presence of Bgtx, suggesting that a7 can inhibit the function of these two growth regulatory proteins.
Gprin1 localizes a7 to the growth cone Gprin1 is a membrane anchored signaling protein that localizes to regions where cytoskeletal remodeling demands are high. In neural cells, Gprin1 can direct the formation of neurites by regulating the function of CDC42 in the growth cone (Nakata and Kozasa 2005) . Because recent studies suggest that Gprin1 can also contribute to receptor localization at the cell surface (Ge et al. 2009; Nordman and Kabbani 2012) , we examined the role of Gprin1 in trafficking and targeting a7 to the plasma membrane. As shown in Fig. 5a and b, Gprin1-cells displayed a significant reduction in the axonal structure, which was accompanied by a noticeable reduction in fBgtx labeling in the GC. To determine the role of Gprin1 in directing a7 to the plasma membrane, cell surface biotinylation experiments were performed in Gprin1-cells and empty vector (pRNAT H1.1) transfected controls. As shown in Fig. 5c , on the basis of the detection of biotinylated a7 proteins, we find a significant reduction in a7 at the cell surface in Gprin1relative to controls. In both the GC and the MP fraction, levels of biotinylated a7 proteins was reduced in Gprin1cells suggesting that Gprin1 plays an essential role in localizing a7 to sites important for axon growth. In these experiments, HCN1 cell surface expression was found unaffected.
Detection of an a7 calcium signal in the growth cone Multiple ion channels and receptors contribute to calcium entry and signaling within the GC (Zheng and Poo 2007) . The temporal and spatial dynamics of calcium within the GC contribute to the elongation, retraction, and turning of the axon via the actions of molecules such as GAP-43 and Gprin1, which regulate the cytoskeleton (Nakata and Kozasa 2005; Zheng and Poo 2007) . We hypothesize that a7/Gprin1 interaction enables calcium signaling leading to cytoskeletal remodeling in the developing axon. To test this we analyzed a7-mediated calcium changes in hippocampal neurons using the calcium indicator Fluo-8 (Hayes et al. 2012) . 0.1% DMSO was used as a vehicle control. The control by itself did not appear to impact calcium levels in the cell (data not shown). As shown in Fig. 6 , PNU treatment was found to promote an overall increase in calcium relative to the control within the soma [+37% (AE 11%)], the axon [+52% (AE 14%)], and the central zone of the GC [+68% (AE 17%)]. In particular, the intracellular calcium rise was strongest within the CZ of the GC, a region that expresses an abundant amount of a7 and Gprin1 (Fig. 2) . In filopodia, PNU treatment was also found to augment calcium levels by 24% (AE 7%). The effect of PNU on intracellular calcium levels was recovered to baseline at~0.5 s. consistent with data on a7 channel kinetics (Fayuk and Yakel 2004) (Fig. 6 ). Choline can endogenously activate a7, thereby critically contributing to brain development (Khiroug et al. 2002) . We confirmed the effects of a7 activation in hippocampal neurons using (1 mM) choline, a concentration previously found to physiologically activate the receptor (Khiroug et al. 2002) . We found that choline increased intracellular calcium levels but most significantly in the GC of the neuron (Fig. 7) . The effect of choline was blocked by Bgtx, underscoring the specificity of this transmitter for a7. Interestingly choline was found to have little to no effect on calcium levels in the soma (Fig. 7a) . The findings suggest that the effects of choline on a7 may be altered by differential mechanisms of transmitter reuptake in various neuronal compartments (Guermonprez et al. 2002) . To confirm that choline and PNU produce similar effects on axon growth, an analysis of axon morphology and pGAP-43 levels was also determined in response to choline. Axon development, GC branching, and pGAP-43 levels were all significantly attenuated by choline and this effect was also blocked by the addition of Bgtx (Fig. 7) . Taken together, the findings indicate that a7 activation mediates intracellular calcium signaling leading to an inhibition in axon development.
To confirm the contribution of Gprin1 in a7-mediated calcium entry into the growing hippocampal neurons, Gprin1-cells were analyzed for the effect of PNU (Fig. 6 ) and choline (Fig. 7) . As shown in Fig. 6 , knockdown of Gprin1 expression is associated with a significant reduction in the cell's calcium responsiveness to PNU treatment (À19% (AE 9%) in the soma; À25% (AE 11%) in the axon; and À53% (AE 8%) in the CZ) relative to an empty plasmid (pRNAT H1.1) control. Similar data was obtained with choline treatment (Fig. 7) , confirming the role of Gprin1 in a7-mediated calcium signaling in the developing axon. These findings also present a first ever demonstration of an a7 calcium signal in the GC, and suggest that this cholinergic signal contributes to the maturation of the axon.
Discussion
A new role for a7 in axon growth In this study we define an interaction between a7 and Gprin1 and demonstrate that this interaction regulates axon growth in hippocampal neurons. We present evidence on the localization and signaling of a7 in GCs as supported by histochemical and western blot detection of the receptor and its interacting protein Gprin1 in developing hippocampal neurons. By interacting with Gprin1, the localization of a7 in the GC appears to enable cholinergic signals to regulate the growth of the axon. Based on this evidence, the interaction of the two proteins and their coupling to a downstream G protein-signaling pathway is proposed to contribute to brain development.
Interestingly, whereas this study demonstrates a role for a7 in axon development, earlier work has shown that knockdown of the a7 can decrease dendritic length and branching in newborn neurons of the dentate gyrus (Campbell et al. 2010; Liu et al. 2010) . This suggests that a7 may differentially contribute to axon and dendrite development by interacting with scaffolding proteins such as Gprin1, which can guide the expression of the receptor to specific neuronal compartments. In this regard, the function of Gprin1 in localizing a7 activity in the developing axon, may be paralleled by another, still unknown, protein that can direct the receptor to dendrites (Campbell et al. 2010) . In future studies, it will be important to examine the proteomic interactions of a7 in maturing dendrites.
Activation of a7 causes local calcium elevation and a collapse of the GC The synaptic localization and high calcium permeability of a7 enables it to influence diverse events, ranging from modulation of transmitter release to synaptic plasticity (McGehee et al. 1995; Gu and Yakel 2011) . The expression and function of a7 in the GC during axon maturation appears dependent on interaction with Gprin1, which directs the trafficking of the receptor to the cell surface and the central zone. This positions a7 at sites where developmental demands are high, and enables it to influence cytoskeletal mechanisms of growth (Lowery and Van Vactor 2009) . As a consequence, a7-mediated elevations in intracellular calcium can arrest axon growth as shown previously for other calcium channels (Kater and Mills 1991; Henley and Poo 2004) . The a7-mediated calcium rise in the GC communicates a 'stop' signal for the growing axon, which is made possible by association with Gprin1 and modulation of the Gao, GAP-43, and CDC42 pathway (Frey et al. 2000; Nakata and Kozasa 2005) . This hypothesis is supported by our observation that activation by a7 (by PNU or choline) promotes dephosphorylation of GAP-43, GTP hydrolysis of CDC42, and negatively influences EB3 microtubule comet velocity in the GC leading to its collapse. Mechanistically this may be achieved via a7-mediated calcium elevations into the GC which can inactivate GAP-43 via calcium sensitive proteins such as calpain (Zakharov and Mosevitsky 2007) and PP2B (Lyons et al. 1994) , leading to inhibition of Ga and CDC42 in the axon (Bromberg et al. 2008a) . It is interesting to consider the possible effects of a7 on other downstream Rho-GTPases involved in growth. RhoA has previously been shown to inhibit axon growth and GC collapse, while Gao can regulate RhoA activity (Bromberg et al. 2008a ). Thus, the ability of a7 to inhibit axon growth may involve the regulation of other possible Rho-GTPases through interaction with the G protein complex. In the long term, activation of a7 is associated with a dramatic reduction in axon length and branching complexity. A functional a7 signal in the growing axon can play an important role in early-life synaptic development (Luo and O'Leary 2005) . Defects in processes such as neurogenesis and axon pruning can lead to pernicious axon growth implicated in a number of developmental brain disorders such as autism, epilepsy, and schizophrenia (Saugstad 2011; Zhou et al. 2012) . Recent findings linking the expression of the a7 gene CHRNA7 to developmental disorders (Yasui et al. 2011; Adams et al. 2012) highlights the role of this receptor in brain development.
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